Back to Journals » Clinical Ophthalmology » Volume 9

Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure

Authors Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas A

Received 6 February 2015

Accepted for publication 4 March 2015

Published 10 April 2015 Volume 2015:9 Pages 633—643

DOI https://doi.org/10.2147/OPTH.S61444

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser


Luciano Quaranta,1,* Ivano Riva,1,* Andreas Katsanos,2 Irene Floriani,3 Marco Centofanti,4,† Anastasios G P Konstas5

1Centre for the Study of Glaucoma, University of Brescia, Brescia, Italy; 2Ophthalmology Department, University of Ioannina, Ioannina, Greece; 3Laboratory of Clinical Research, IRCCS, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; 4DSCMT, University of Tor Vergata, Rome, Italy; 5Glaucoma Unit, 1st University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece

*These authors contributed equally to this work; †Dr Centofanti passed away on 1 March 2015

Abstract: Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.

Keywords: prostaglandin analogue, glaucoma, ocular hypertension

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]